Aytu BioPharma Inc. (NASDAQ:AYTU) Given Average Recommendation of “Hold” by Brokerages

Shares of Aytu BioPharma Inc. (NASDAQ:AYTU) have been assigned a consensus recommendation of “Hold” from the five ratings firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $9.3333.

Several equities research analysts have recently issued reports on the company. Ascendiant Capital Markets raised their target price on Aytu BioPharma from $12.50 to $13.00 and gave the company a “buy” rating in a research report on Wednesday, December 10th. Maxim Group reduced their price target on shares of Aytu BioPharma from $9.00 to $7.00 and set a “buy” rating for the company in a research report on Thursday, September 25th. Zacks Research raised shares of Aytu BioPharma from a “strong sell” rating to a “hold” rating in a research report on Monday, November 24th. Wall Street Zen cut shares of Aytu BioPharma from a “buy” rating to a “hold” rating in a research note on Friday, September 26th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Aytu BioPharma in a research note on Friday, January 9th.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in AYTU. Daytona Street Capital LLC bought a new position in Aytu BioPharma during the fourth quarter worth about $26,000. Dimensional Fund Advisors LP purchased a new stake in shares of Aytu BioPharma during the 3rd quarter valued at approximately $58,000. FNY Investment Advisers LLC lifted its stake in shares of Aytu BioPharma by 24,207.7% during the 4th quarter. FNY Investment Advisers LLC now owns 31,600 shares of the company’s stock valued at $82,000 after buying an additional 31,470 shares in the last quarter. Two Sigma Investments LP boosted its holdings in Aytu BioPharma by 96.2% in the 3rd quarter. Two Sigma Investments LP now owns 68,736 shares of the company’s stock worth $129,000 after buying an additional 33,701 shares during the period. Finally, Persistent Asset Partners Ltd purchased a new position in Aytu BioPharma in the 3rd quarter valued at approximately $117,000. Hedge funds and other institutional investors own 33.49% of the company’s stock.

Aytu BioPharma Price Performance

Aytu BioPharma stock opened at $2.61 on Thursday. Aytu BioPharma has a 52 week low of $0.95 and a 52 week high of $3.07. The company’s 50 day moving average price is $2.40 and its two-hundred day moving average price is $2.32. The stock has a market cap of $26.60 million, a P/E ratio of -0.86 and a beta of 0.32. The company has a quick ratio of 1.08, a current ratio of 1.23 and a debt-to-equity ratio of 0.45.

Aytu BioPharma (NASDAQ:AYTU) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.02). The business had revenue of $13.89 million for the quarter, compared to analysts’ expectations of $17.92 million. Aytu BioPharma had a negative net margin of 20.52% and a positive return on equity of 17.86%.

About Aytu BioPharma

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.